Atherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscle

Sefaa Al-aryahic, Danielle Kamato, Robel Getachew, Wenhua Zheng, Simon J Potocnik, Neale Cohen, Daniel Guidone, Narin Osman, Peter J Little

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


Pharmaceutical interventions for diabetes aim to control glycaemia and to prevent the development of complications, such as cardiovascular diseases. Some anti-hyperglycaemic drugs have been found to have adverse cardiovascular effects in their own right, limiting their therapeutic role. Glucokinase activity in the pancreas is critical in enhancing insulin release in response to hyperglycaemia. Glucokinase activators (GKAs) are novel agents for diabetes which act by enhancing the formation of glucose-6-phosphate leading to increased insulin production and subsequent suppression of blood glucose. Little, however, is known about the direct effects of GKAs on cardiovascular cells.
Original languageEnglish
Article number80
Pages (from-to)1 - 15
Number of pages15
JournalCardiovascular Diabetology
Issue number1
Publication statusPublished - 2014

Cite this